



Molecular docking study of *Momordica charantia* Linn phytoconstituent with caspase 3 and implications for renoprotective actions in diabetes mellitus

Mohan Krishna Ghanta¹, Swapna R Nayaka¹, Poojith Nuthalapati², AK Afzal Khan¹, Panchanathan Elango^{3*}, LVKS Bhaskar^{4*}

¹Department of Pharmacology, MVJ Medical College and Research Hospital, Hoskote, Bangalore-562114, Karnataka, India

²PJ Biosys, Irving, Texas, USA-75038

³Department of Pharmacology, Bharath Medical College and Hospital, Agaram Main Road, Selaiyur, Chennai, Tamil Nadu, India

⁴Department of Zoology, Guru Ghasidas Vishwavidyalaya (GGU), Bilaspur-495551, Chhattisgarh, India

ARTICLE INFO

Article Type:
Original

Article History:

Received: 2 Apr. 2021

Accepted: 10 Oct. 2021

Published online: 30 Oct. 2021

Keywords:

D-Galacturonic acid

Caspase 3

Bitter gourd

In-silico

ABSTRACT

Introduction: Caspase 3, an apoptosis executioner, inhibition may be beneficial for diabetes, nephropathies, neurodegenerative disease treatments and in areas of regenerative medicine. Since early traditional medicine, plant extracts comprised the major treatments of many ailments. Phytoconstituents have been a prime source for therapeutics, which are abundantly available resources. Therefore, with the interest to identify potential anti-apoptotic agents in plant extracts, D-galacturonic acid (DGA) was selected for screening anti-caspase 3 activity as it is the major constituent in *Momordica charantia* (bitter melon) and many other fruits' pectin composition.

Objectives: The present study aimed to evaluate activity of major phytoconstituent of *M. charantia* extract, DGA against caspase 3.

Materials and Methods: The chemical structure of the ligand was from obtained PubChem database, and the protein structure was procured from PDB database. Molecular docking study was performed using AutoDock version 4.2.

Results: This study states the interactions of DGA with GLU'124, LYS'137 and ARG'164 amino acids of caspase 3, where GLU'124, LYS'137 amino acid interactions are important for stability of caspase 3 enzyme.

Conclusion: The interactions between DGA and caspase 3 revealed in this study may be helpful in characterizing the medicinal property of this phytoconstituent in the bitter melon extract by future studies.

Implication for health policy/practice/research/medical education:

Momordica charantia has varying actions which are proven beneficial to human health. Characterizing the phytochemicals of *M. charantia* extract and further preclinical/clinical studies may provide a potential drug candidate for renoprotection and many other ailments involving caspase 3 like neurodegenerative diseases and malignant disorders.

Please cite this paper as: Ghanta MK, Nayaka SR, Nuthalapati P, Afzal Khan AK, Elango P, Bhaskar LVKS. Molecular docking study of *Momordica charantia* Linn phytoconstituent with caspase 3 and implications for renoprotective actions in diabetes mellitus. J Nephroarmacol. 2025;14(1):e10394. DOI: 10.34172/npj.2022.10394.

Introduction

Apoptosis is a programmed cell death mediated by many pathways including effector caspases-3, 6 and 7 which targets >600 protein molecules, and consistently linked to diabetic kidney disease (1-3). Caspase 3 and 9 were found as one of the potential factors to cause neurodegenerative diseases (4,5). Small molecule observations into their successful mediation will thus provide clues for the

treatment of these pathogenesis (6). The cysteine-aspartic acid protease (caspase) family includes the caspase 3 enzyme. The sulfhydryl group of cysteine-285 (Cys-285) and the imidazole ring of histidine-237 (His-237) form the catalytic site of caspase-3. His-237 stabilizes the main aspartate residue's carbonyl group, while Cys-285 attacks to cleave the peptide bond. Through hydrogen bonding, Cys-285 and Gly-238 also help to stabilize the substrate-

*Corresponding authors: Bhaskar VKS Lakkakula, Email: lvksbhaskar@gmail.com, and Elango Panchanathan, Email: drpelango@yahoo.com, elango.pharmacology@bmch.ac.in

enzyme complex's tetrahedral transition state. Caspase-3 prefers the peptide aspartate-glutamate-valine-aspartate-glycine (DEVGD) *in-vitro*, with dissociation emerging on the carboxyl side of the 2nd aspartic acid residue (between D and G) (7). Of 497-residue of protein, residues 124–162, are involved in enzyme inhibition (8).

There are many studies on *Momordica charantia* plant extract showing caspase 3 stimulation against some cancer experimental models (9,10). While some studies have also shown the caspase 3 inhibitory or down regulation in neurodegenerative experimental models (11-13). In context to renoprotection, *Momordica charantia* extract (MCE) has been shown to restore serum glucose levels and renal damage in Sprague-Dawley rat model, which may imply its effectiveness (14). Therefore, we planned to conduct this study to predict the role of D-galacturonic acid (DGA) as an inhibitor of caspase 3 which is one of the major phytoconstituent of *Momordica charantia*, DGA.

Objectives

The objective of this study was to demonstrate the action of DGA against caspase 3 using *in-silico* methods.

Materials and Methods

DGA is uronic acid, a product of oxidative reaction of D-galactose and an important compound for many metabolic reactions in human body (15). The chemical structure of the DGA was obtained from PubChem database (PubChem ID: 439215) [<http://www.ncbi.nlm.nih.gov/pccompound>] and the 3-D structure was extracted from Chem Draw Ultra 11.0. The structure confirmation and ligand energy minimization were conducted with PRODRG server (16). The chemical properties of ligand were explored with DataWarrior software v04.06.00. The crystal 3-D structure of protein was taken from PDB database (PDB ID: 1GFW). Binding sites of target receptors and prediction for ligand binding was explored using CASTp server.

Docking analysis was performed using AutoDock Tool v.1.5.6 and AutoDock v 4.2 programs from Scripps Research Institute (<http://www.scripps.edu/mb/olson/>

[doc/autodock](#)) as in method described by previous study and, for PyMol molecular viewer and PoseView as well (15).

Results

The DGA showed interactions with GLU'124, LYS'137 and ARG'164 (Figure 1). The ligand efficiency of DGA was 0.31. The inhibition constant was 1.12 μ M and Van der Waal's interaction energy was -3.65 kcal/mol. The DGA interacted with caspase 3 forming hydrogen bonds at GLU'124 and LYS'137. The type of bond involved in the interaction is stated in the Table 1.

Discussion

The DGA showed interactions with glutamate, lysine and arginine residues of caspase 3 catalytic site. The ligand efficiency of DGA was 0.31, which implies the drug-likeness of the compound (17). The drug-likeness properties of DGA were already reported from our previous studies (15).

MCEs obtained through water extraction and alcohol precipitation method contained polysaccharides and DGA as major constituent (13). This major constituent was taken for screening against catalytic site of caspase 3 in our study using *in-silico* method. DGA showed moderate binding activity with GLU 124, LYS 137 and ARG 164 amino acid residues of caspase 3 protein. Previous study on this protein structure demonstrated that any interactions or mutations between 124-162 amino acid residues of this protein may inactivate the caspase 3 protein enzyme activity (8). Another study inferred that presence of glutamic amino residues favors binding to ligands causing inhibition of caspase 3 protein activity (18). Hence DGA interactions with GLU 124 and LYS 137 may show significant role in regulation with caspase 3 activity.

In context with caspase 3 regulation with MCE, varying activity have been reported in different disease experimental models. In experimental models of cancer diseases, the caspase 3 enzyme activity is found to be down-regulated or compromised whereas the MCE




Figure 1. Molecular interactions of DGA with caspase 3 amino acid residues. A- 2D view, B- 3D view.

Table 1. Factor scores and protein-ligand complex formation

Ligand	Protein PDB ID	Binding amino acid Residues	Binding energy (kcal / mol)	Inhibition constant μM	VDW_HB desolv_ energy (kcal/mol)	Ligand efficiency
D-Galacturonic acid	Caspase 3 (1GFW)	GLU`124/OE2, LYS`137/HZ2, ARG`164/1HH2	-4.03	1.12	-3.65	0.31

GLU: glutamate; LYS: lysine; ARG: arginine; OE2, HZ2 and 1HH2 are atom names.

showed up-regulation of caspase 3 (9,10). In experimental models of neurodegenerative diseases, the caspase 3 activity was up-regulated or aggravated but MCE showed attenuation (11-13). This varying activity of MCE in previous studies and our present study results may infer that DGA exhibits mixed activity on caspase 3. This mixed function of the MCE may require further molecular experimental studies to demonstrate the MCE-caspase 3 activity. However, in this study, MCE phytoconstituent DGA showed interactions revealing inhibitory actions against caspase 3, vital for renoprotection, which has been substantiated by previous studies that caspase 3 mediates the cleavage of gasdermin E, a tumor growth suppressor, forms gasdermin E-N fragments known to change the cell death pattern from apoptosis to inflammatory necrotic events in diabetes (8,19-21).

Conclusion

The molecular actions of DGA in relation to caspase 3 was predicted in this study which may provide insights for future studies aiming to study molecular events of MCE-caspase 3 actions and for new drug developments as well.

Limitations of the study

This study included only DGA of MCE against anti-caspase 3 activity. Further studies are required to evaluate the role of other phytochemicals of MCE.

Acknowledgements

The authors are thankful to Sri Ramachandra Institute of higher education and research (SRIHER-DU), Chennai for providing financial support in the form of Founder Chancellor Shri N.P.V. Ramasamy Udayar Research Fellowship no. PhD (RR) 431-F.T./I/2015.

Authors' contribution

Conceptualization: Mohan Krishna Ghanta, LVKS Bhaskar and Panchanathan Elango.

Data curation: LVKS Bhaskar and Mohan Krishna Ghanta.

Formal analysis: Mohan Krishna Ghanta.

Funding acquisition: Mohan Krishna Ghanta, LVKS Bhaskar and Panchanathan Elango.

Investigation: Mohan Krishna Ghanta.

Methodology: LVKS Bhaskar and Mohan Krishna Ghanta.

Project administration: LVKS Bhaskar.

Resources: LVKS Bhaskar, AK Afzal Khan, Poojith

Nuthalapati and Swapna R Nayaka.

Supervision: Mohan Krishna Ghanta, LVKS Bhaskar and Panchanathan Elango.

Validation: LVKS Bhaskar and Mohan Krishna Ghanta.

Visualization: Mohan Krishna Ghanta, LVKS Bhaskar and Panchanathan Elango.

Writing—original draft: LVKS Bhaskar and Mohan Krishna Ghanta.

Writing—review and editing: AK Afzal Khan, Poojith Nuthalapati and Swapna R Nayaka.

Conflicts of interest

The authors declare that they have no competing interests.

Ethical issues

Ethical issues (including plagiarism, data fabrication, double publication) have been completely observed by authors.

Funding/Support

This study was funded by Founder Chancellor Shri N.P.V. Ramasamy Udayar Research Fellowship no. PhD (RR) 431-F.T./I/2015.

References

1. Van Laer L, Huizing EH, Verstreken M, van Zuijlen D, Wauters JG, Bossuyt PJ, et al. Nonsyndromic hearing impairment is associated with a mutation in DFNA5. *Nat Genet.* 1998;20:194–197. doi: 10.1038/2503.
2. Op de Beeck K, Van Camp G, Thys S, Cools N, Callebaut I, Vrijens K, et al. The DFNA5 gene, responsible for hearing loss and involved in cancer, encodes a novel apoptosis-inducing protein. *Eur J Hum Genet.* 2011;19:965–973. doi: 10.1038/ejhg.2011.63.
3. Wang Y, Gao W, Shi X, Ding J, Liu W, He H, et al. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. *Nature.* 2017;547:99-103. doi: 10.1038/nature22393.
4. Bredesen DE. Neurodegeneration in Alzheimer's disease: caspases and synaptic element interdependence. *Mol Neurodegener.* 2009;4:27. doi: 10.1186/1750-1326-4-27.
5. D'Amelio M, Cavallucci V, Ceconi F. Neuronal caspase-3 signaling: not only cell death. *Cell Death Differ.* 2010;17:1104-14. doi: 10.1038/cdd.2009.180.
6. Zhang C, Zhu X, Li L, Ma T, Shi M, Yang Y, et al. A small molecule inhibitor MCC950 ameliorates kidney injury in diabetic nephropathy by inhibiting NLRP3 inflammasome activation. *Diabetes Metab Syndr Obes.* 2019;12:1297-309. doi: 10.2147/DMSO.S199802.
7. Fuentes-Prior P, Salvesen GS. The protein structures that

- shape caspase activity, specificity, activation and inhibition. *Biochem J.* 2004;384:201-32. doi: 10.1042/BJ20041142.
8. Riedl SJ, Renatus M, Schwarzenbacher R, Zhou Q, Sun C, Fesik SW, et al. Structural basis for the inhibition of caspase-3 by XIAP. *Cell.* 2001;104:791-800. doi: 10.1016/S0092-8674(01)00274-4.
 9. Thiagarajan S, Arapoc DJ, Husna Shafie N, Keong YY, Bahari H, Adam Z, et al. *Momordica charantia* (Indian and Chinese Bitter Melon) extracts inducing apoptosis in human lung cancer cell line A549 via ROS-mediated mitochondria injury. *Evid Based Complement Alternat Med.* 2019;2019:2821597. doi: 10.1155/2019/2821597.
 10. Ray RB, Raychoudhuri A, Steele R, Nerurkar P. Bitter melon (*Momordica charantia*) extract inhibits breast cancer cell proliferation by modulating cell cycle regulatory genes and promotes apoptosis. *Cancer Research.* 2010;70:1925-31. doi: 10.1158/0008-5472.CAN-09-3438.
 11. Kim KB, Lee S, Kang I, Kim JH. *Momordica charantia* ethanol extract attenuates H₂O₂-Induced cell death by its antioxidant and anti-apoptotic properties in human neuroblastoma SK-N-MC cells. *Nutrients.* 2018;10:1368. doi: 10.3390/nu10101368.
 12. Duan ZZ, Zhou XL, Li YH, Zhang F, Li FY, Su-Hua Q. Protection of *Momordica charantia* polysaccharide against intracerebral hemorrhage-induced brain injury through JNK3 signaling pathway. *J Recept Signal Transduct Res.* 2015;35:523-9. doi: 10.3109/10799893.2014.963871.
 13. Gong J, Sun F, Li Y, Zhou X, Duan Z, Duan F, et al. *Momordica charantia* polysaccharides could protect against cerebral ischemia/reperfusion injury through inhibiting oxidative stress mediated c-Jun N-terminal kinase 3 signaling pathway. *Neuropharmacology.* 2015;91:123-34. doi: 10.1016/j.neuropharm.2014.11.020.
 14. Offor U, Naidu EC, Ogedengbe OO, Jegede AI, Peter AI, Azu OO. Nephrotoxicity and highly active antiretroviral therapy: Mitigating action of *Momordica charantia*. *Toxicol Rep.* 2018;5:1153-60. doi: 10.1016/j.toxrep.2018.09.003.
 15. Ghanta M, Panchanathan E, Lakkakula BVKS, Narayanaswamy A, Abhinand PA, Antony S. Molecular docking analysis of phytoconstituent from *Momordica charantia* with Guanylate Cyclase catalytic domain. *Bioinformatics.* 2018;14:378-83. doi: 10.6026/97320630014378.
 16. Schüttelkopf AW, van Aalten DM. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. *Acta Crystallogr D Biol Crystallogr.* 2004;60:1355-63. doi: 10.1107/S0907444904011679.
 17. Abad-Zapatero C. Ligand efficiency indices for effective drug discovery. *Expert Opin Drug Discov.* 2007;2:469-88. doi: 10.1517/17460441.2.4.469.
 18. Qi Wang, Robert H. Mach, David E. Reichert. Docking and 3D-QSAR Studies on Isatin Sulfonamide Analogues as Caspase-3 Inhibitors. *Journal of Chemical Information and Modeling.* 2009;49:1963-73. doi: 10.1021/ci900144x.
 19. Siboto A, Sibiya N, Khathi A, Ngubane P. The effects of *Momordica balsamina* methanolic extract on kidney function in STZ-induced diabetic rats: effects on selected metabolic markers. *J Diabetes Res.* 2018;2018: 7341242. doi: 10.1155/2018/7341242.
 20. Ludidi A, Baloyi MC, Khathi A, Sibiya NH, Ngubane PS. The effects of *Momordica balsamina* methanolic extract on haematological function in streptozotocin-induced diabetic rats: Effects on selected markers. *Biomedicine & Pharmacotherapy.* 2019;116:108925. doi: 10.1016/j.biopha.2019.108925.
 21. Wen S, Wang ZH, Zhang CX, Yang Y, Fan QL. Caspase-3 promotes diabetic kidney disease through gasdermin e-mediated progression to secondary necrosis during apoptosis. *Diabetes Metab Syndr Obes.* 2020;13:313-23. doi: 10.2147/DMSO.S242136.

Copyright © 2025 The Author(s); Published by Society of Diabetic Nephropathy Prevention. This is an open-access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.